Company Encyclopedia
View More
name
Oxford BioDynamics PLC
OBD.UK
News
View More

REG - AIM - AIM Notice - 10/11/2025

The London Stock Exchange has admitted Nativo Resources PLC and Oxford BioDynamics Plc to trading on AIM as of November 10, 2025. Nativo Resources PLC has 49,999,999 ordinary shares of 0.15p each, while Oxford BioDynamics Plc has 208,333,332 ordinary shares of GBP 0.01 fully paid. For further inquiries, Market Operations can be contacted at 020 7797 4310.

London Stock Exchange·
UK
OBD
0.00%
London Stock Exchange·
UK
OBD
0.00%

UK equities mixed as investors assess corporate earnings amid fiscal worries

UK equities ended mixed as investors evaluated corporate earnings amid concerns over potential tax hikes. The FTSE 100 fell 0.04%, while the FTSE 250 rose 0.5%. Key highlights include Kingfisher's 14.6% surge after raising its profit forecast, and Serco's 4.7% increase following a $972 million contract with the US Air Force. However, the broader healthcare sector declined 1.7%, with Oxford BioMedica down 6.5%. Overall, British business activity showed signs of slowing, raising concerns about future economic confidence.

Reuters·
UK
OBD
0.00%
Reuters·
UK
OBD
0.00%

RCS - Oxford BioDynamics - Study confirms clinical utility of EpiSwitch CiRT

Oxford BioDynamics plc announced the publication of interim results from its PROWES trial, demonstrating the clinical utility of its EpiSwitch CiRT test in guiding immunotherapy decisions for cancer patients. The study showed that CiRT influenced treatment choices in 61% of cases, with high sensitivity and specificity. The company plans to apply for inclusion in the US National Comprehensive Cancer Network guidelines, aiming to enhance adoption and improve patient outcomes while reducing treatment costs. CiRT is currently available in the UK and US with reimbursement options.

London Stock Exchange·
UK
OBD
0.00%
London Stock Exchange·
UK
OBD
0.00%

Oxford BioDynamics Announces Collaboration With Google Cloud

Oxford Biodynamics PLC :OXFORD BIODYNAMICS - COLLABORATION WITH GOOGLE CLOUDOXFORD BIODYNAMICS - COLLABORATION WITH GOOGLE CLOUD

Reuters·
UK
OBD
0.00%
Reuters·
UK
OBD
0.00%

Oxford BioDynamics Sees Shift in Shareholder Structure

Oxford BioDynamics PLC has announced a significant change in its shareholder structure, with Trafalgar Capital Management acquiring 3.3% of the voting rights. This shift may influence the company's strategic decisions and market position, reflecting increased interest from international stakeholders. According to TipRanks’ AI Analyst, GB:OBD is rated Neutral, highlighting financial challenges but also potential growth opportunities through recent strategic achievements. Oxford BioDynamics focuses on developing epigenetic biomarkers for personalized medicine, with a current market cap of £10.57M.

Tip Ranks·
UK
OBD
0.00%
Tip Ranks·
UK
OBD
0.00%